SK3 Group Inc. (SKTO)

[I-Glow]

Here is the problem with the news you posted - there are very important details missing.

All of the studies but one were conducted on rats and at the low end of the dosage of CBD was 2.5mg/kg and that went to as high as 10mg/kg.

2.5mg/kg equals 5.5mg/lb - and 10mg/kg converts to 22mg/kg.

For a 150lb person that would be between 825 and 3,330mg of CBD per day!

The only Phase 3 clinical trial using CBD was Sativex to treat pain in cancer patients - keep in mind this was one of the long time established myths about CBD.

Sativex is a 1:1 ratio of THC and CBD produced by GW Pharmaceuticals.

In the Phase 3 clinical trials - it failed to alleviate the pain in cancer patients.

An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday.

GW, which is developing the drug Sativex for pain in collaboration with Japan's Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo.

http://www.reuters.com/article/2015/01/08/us-gw-pharma-epilepsy-idUSKBN0KH13U20150108

The part about the US Government owning a patent on cannabinoids:

In addition to the NIDA’s public acknowledgment, the government has made other admissions of the medical benefits of cannabis: it holds a patent on cannabinoids for use as antioxidants and neuroprotectants.

The government patent is misunderstood - I see people post this all the time but haven't taken the time to read it.

The US patent was in 2003 - (Cannabinoids as antioxidants and neuroprotectants)...

Saying that US Government has a patent on Cannabinoids is a blanket statement that isn't accurate.

The Patent doesn't give the US Government ownership of marijuana.

First, products of nature are not patentable.

Second, in the US Patent - it defines the method of use not the compound.

The only thing that the US patent covers is the rights to methods of using certain cannabinoids for treating oxidative stress.

1. A method of treating diseases caused by oxidative stress, comprising administering a therapeutically effective amount of a cannabinoid that has substantially no binding to the NMDA receptor to a subject who has a disease caused by oxidative stress.

2. The method of claim 1, wherein the cannabinoid is nonpsychoactive.

GW Pharmaceuticals has over 39 patents involving marijuana

IG